Compare INTZ & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | INKT |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 51.7M |
| IPO Year | 2020 | 2021 |
| Metric | INTZ | INKT |
|---|---|---|
| Price | $1.46 | $12.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.25 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 88.9K | 19.7K |
| Earning Date | 11-11-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,290,000.00 | N/A |
| Revenue This Year | $38.09 | N/A |
| Revenue Next Year | $27.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.49 | N/A |
| 52 Week Low | $0.35 | $4.56 |
| 52 Week High | $7.34 | $76.00 |
| Indicator | INTZ | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 51.40 |
| Support Level | $1.40 | $11.48 |
| Resistance Level | $1.55 | $13.34 |
| Average True Range (ATR) | 0.09 | 0.84 |
| MACD | 0.02 | 0.27 |
| Stochastic Oscillator | 65.52 | 67.49 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The group offers customers to access its threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol (IP) addresses. The company's product consists of On-Premise Network Protection, Cyber Threat Consulting, Cloud Network Security, and Endpoint Protection. Its solutions are INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. Its end-user customers include the U.S. federal government, state and local government entities, large and diversified conglomerates, and manufacturing entities.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.